Group 1 - Natera (NTRA) has seen its shares increase nearly 50% this year, indicating strong market interest despite the company not yet being profitable [4][9] - The company has been recognized as the IBD 50 Growth Stock To Watch, suggesting it presents a potential buying opportunity for investors [4] - Medical stocks, including Natera, are outperforming the broader market and are featured prominently on the IBD 50 growth list [5]